| Net Cash Provided by (Used in) Operating Activities |
$76,091,000 |
USD |
11% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$30,595,000 |
USD |
141% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Investing Activities |
$99,997,000 |
USD |
-41% |
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
431,000,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
136,937,989 |
shares |
0.38% |
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$6,689,000 |
USD |
-35% |
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$11,832,000 |
USD |
-49% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Valuation Allowance |
$0 |
USD |
|
Q4 2024 |
FY 2024 |
| Deferred Tax Assets, Gross |
$27,297,000 |
USD |
54% |
Q4 2024 |
FY 2024 |
| Deferred Income Tax Expense (Benefit) |
$2,870,000 |
USD |
-40% |
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$14,152,000 |
USD |
3.5% |
Q4 2024 |
FY 2024 |
| Unrecognized Tax Benefits |
$0 |
USD |
|
Q3 2025 |
Q3 2025 |
| Additional Paid in Capital |
$657,859,000 |
USD |
0.46% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$27,297,000 |
USD |
54% |
Q4 2024 |
FY 2024 |
| Share-based Payment Arrangement, Expense |
$2,998,000 |
USD |
117% |
Q3 2025 |
Q3 2025 |
| Interest Expense |
$8,135,000 |
USD |
351% |
Q1 2024 |
Q1 2024 |